Gnrh    (DrugBank: GnRH)

1 disease
IDDisease name (Link within this page)Number of trials
76Pituitary gonadotropin secretion hyperthyroidism6

76. Pituitary gonadotropin secretion hyperthyroidism    [ 25 clinical trials,   41 drugs,   (DrugBank: 11 drugs),   3 drug target genes,   10 drug target pathways]
Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 25 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000038202
2020-09-012020-09-13AMH combined INHB for the diagnosis of female central precocious pubertyAMH combined INHB for the diagnosis of female central precocious puberty Central precocious pubertyGold Standard:GnRHa provoctive test;Index test:Anti Mullerian hormone, Inhibin B;Capital Institute of PediatricsNULLRecruiting58FemaleTarget condition:150;Difficult condition:150China
2ChiCTR1800017120
2018-08-012018-07-12A real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girlsA real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girls. precocious pubertyCase series:rhGH therapy;The Children's Hospital, Zhejiang University School of MedicineNULLRecruiting312FemaleCase series:700;China
3ChiCTR1800016768
2018-06-252018-06-22A real world study on the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girlsA real world study on the efficacy and safety of the combination therapy of GnRHa and rhGH in the treatment of central precocious puberty or rapid progressive adolescent girls Central precocious puberty or rapid progressive adolescenceCase series:GnRHa combined with rhGH;The Children's Hospital, Zhe Jiang University School of MedcineNULLRecruiting612FemaleCase series:700;China
4NCT02993926
(ClinicalTrials.gov)
June 24, 201713/12/2016A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese ParticipantsAn Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious PubertyPuberty, Central PrecociousDrug: Enantone;Drug: GnRH agonistTakedaNULLCompletedN/AN/AAll108China
5NCT00667446
(ClinicalTrials.gov)
December 200824/4/2008Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious PubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious PubertyPrecocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious PubertyDrug: Leuprolide Acetate 3 Month DepotAbbVie (prior sponsor, Abbott)NULLCompletedN/AN/AAll72Phase 3United States;Puerto Rico
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00438217
(ClinicalTrials.gov)
May 200621/2/2007Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenAnalysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenCentral Precocious PubertyDrug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)University of PisaNULLRecruiting1 Year18 YearsBoth100Phase 4Italy